MedTrace Logo

Capadenoson in Angina Pectoris

NCT00518921 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-01-13

No results posted yet for this study

Summary

This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.

Conditions

  • Chronic Stable Angina

Interventions

DRUG

Capadenoson (BAY 68-4986)

1mg Capadenoson, double dummy

DRUG

Capadenoson (BAY 68-4986)

2mg Capadenoson, double dummy

DRUG

Capadenoson (BAY 68-4986)

4mg Capadenoson, double dummy

DRUG

Placebo

Placebo, double dummy

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Completion
2008-11-30

Countries

  • Czechia
  • Hungary
  • Israel
  • Italy
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518921 on ClinicalTrials.gov